Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
Titel:
Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
Auteur:
Choueiri, Toni K. Hessel, Colin Halabi, Susan Sanford, Ben Michaelson, M. Dror Hahn, Olwen Walsh, Meghara Olencki, Thomas Picus, Joel Small, Eric J. Dakhil, Shaker Feldman, Darren R. Mangeshkar, Milan Scheffold, Christian George, Daniel Morris, Michael J.